Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sugammadex Sodium in Reversal of Neuromuscular Blockade: NCT06436768 Clinical Landscape Report 2026
28 September 2026
NCT06436768 clinical landscape for Reversal of Neuromuscular Blockade: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Crizanlizumab-TMCA in Vaso-occlusive crisis: NCT06439082 Clinical Landscape Report 2026
28 September 2026
NCT06439082 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) in Myasthenia Gravis: NCT06447597 Clinical Landscape Report 2026
28 September 2026
NCT06447597 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Desidustat in Hemoglobin SC Disease: CTRI/2024/06/068363 Clinical Landscape Report 2026
28 September 2026
CTRI/2024/06/068363 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Telitacicept in Myasthenia Gravis: NCT06456580 Clinical Landscape Report 2026
28 September 2026
NCT06456580 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT06464458 Clinical Landscape Report 2026
28 September 2026
NCT06464458 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cladribine in Myasthenia Gravis: NCT06463587 Clinical Landscape Report 2026
28 September 2026
NCT06463587 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: ACTRN12624000825550 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000825550 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Zilucoplan in Myasthenia Gravis: NCT06471361 Clinical Landscape Report 2026
28 September 2026
NCT06471361 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BMS-986470 in Anemia, Sickle Cell: NCT06481306 Clinical Landscape Report 2026
28 September 2026
NCT06481306 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Hematologic Diseases: PACTR202406801520269 Clinical Landscape Report 2026
28 September 2026
PACTR202406801520269 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TLB-001 in Idiopathic Pulmonary Fibrosis: ACTRN12624000813583 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000813583 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…